New Treatment Options Needed for Immune Thrombocytopenia
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Thrombotic Disorders
THROMBOTIC DISORDERS
FEATURE
LATEST ARTICLES
Extended Oral Anticoagulation Therapy for First Unprovoked Deep Vein Thrombosis
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
Dabigatran Safe, Effective for Managing VTE in Pediatric Trials
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
Using the PLASMIC Score to Risk Stratify Patients With Immune Thrombotic Thrombocytopenic Purpura
Utilizing a PLASMIC score-based algorithm may reduce treatment costs by reducing overutilization of therapeutic plasma exchange and expert consultations.
From Fatal to Curable: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Relapse Predictors in Immune Thrombotic Thrombocytopenic Purpura After Rituximab Treatment
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Heterozygous FXII Deficiency Appears Unrelated to the Incidence of Thrombotic Events
Similar rates of thrombotic events occurred in patients with FXII deficiency and unaffected controls.
Low Antigen Level May Be an Indication for Splenectomy in Relapsing Thrombotic Thrombocytopenic Purpura
Researchers described 2 patients with refractory thrombotic thrombocytopenic purpura who regained normal ADAMTS13 levels after splenectomy.
Equivalence Between Rituximab Originator and Biosimilar in Immune Thrombocytopenic Purpura
Platelet counts, ADAMTS13 recovery, and infective complications were not significantly different between the 2 treatment groups.
Managing Pediatric Systemic Lupus Erythematosus in Thrombotic Thrombocytopenic Purpura
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Risk Factors for Recurrent Venous Thromboembolism in Patients With Sickle Cell Disease
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Caplacizumab Associated With Improved Outcomes in Acquired Thrombotic Thrombocytopenic Purpura
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Decreased Relapse, Mortality Rates With Rituximab in Acquired Thrombotic Thrombocytopenic Purpura
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
Second-Line Treatment Outcome Variability in Children With Immune Thrombocytopenia
Though all evaluated second-line treatments improved clinical outcomes, romiplostim was found to be the most effective at 6 months.
VTE-BLEED Risk Score Reliably Identifies Patients With PE at Risk for Major Bleeding
The VTE-BLEED risk score identified patients with pulmonary embolism at risk for in-hospital majorbleeding.
Outcomes With Eculizumab and Responses to Withdrawal for Atypical Hemolytic Uremic Syndrome
Among patients who underwent eculizumab withdrawal, 76.9% remained in remission during the course of the study.
Using Neural Networks to Assess Risk for Deep Vein Thrombosis
The neural network developed in this study yielded a false-negative rate of 0.22%.
Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Long-Term Outcomes of Fostamatinib for Immune Thrombocytopenia
Researchers reviewed outcomes from several phase 3 trials assessing the feasibility of fostamatinib for immune thrombocytopenia.
Managing Neonatal Thrombocytopenia of Alloimmune Origin
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.
Apixaban May Reduce Risk for Venous Thromboembolism in Patients With Cancer
Significantly fewer patients receiving apixaban experienced thromboembolism and major bleeding compared with patients receiving placebo.
No Association Found Between Locations of Venous Thromboembolism and Occult Cancer
An analysis of 2300 patients found similar prevalence of abdominal, pelvic, and thoracic cancer in patients with deep vein thrombosis and pulmonary embolism.
Better Guidelines for Diagnosing Pulmonary Embolism During Pregnancy Needed
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Managing Venous Thromboembolism in Transgender Women Receiving Hormone Therapy
Transgender women receiving hormone replacement therapy may be at an increased risk for thromboembolism, though data and recommendations vary across studies.
Lack of Thromboprophylactic Benefit With Rivaroxaban in Ambulatory Patients With Cancer
Patients receiving rivaroxaban did not experience a statistically significant decrease in thrombotic events compared with patients receiving placebo.
Novel Risk Factors for Venous Thromboembolism in Pregnancy and Postpartum
Researchers assessed potential risk factors for venous thromboembolism during pregnancy and postpartum in more than 100,000 Japanese women.
Thromboprophylaxis May Not Benefit Patients With Advanced Cancer in Palliative Care
Thromboprophylactic treatment and serum albumin levels were not found to be associated with deep vein thrombosis incidence.
The Challenges of Treating Thromboinflammation
Because dysregulation of coagulation is a key feature of thromboinflammation, coagulation inhibitors may have therapeutic potential.
Case Study: Systemic Lupus Erythematosus With Lupus Nephritis and Thrombotic Microangiopathy
A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month.
Antithrombin Deficiency May Be Undertreated With Standard Heparin Therapy
Antifactor Xa activity after heparin spiking was lower in plasma samples from antithrombin-deficient patients compared with control samples.
Cablivi Approved for Acquired Thrombotic Thrombocytopenic Purpura
First FDA-approved therapy specifically indicated for the treatment of aTTP
Safety Comparison of Apixaban vs Rivaroxaban for Thromboembolism Prevention
Researchers conducted the first real world study to compare the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.
A Serological Tool to Phenotypically Characterize Primary Antiphospholipid Syndrome
Researchers assessed the prevalence of various antiphosphatidylserine/prothrombin antibodies in patients with primary antiphospholipid syndrome.
Lower Platelet Transfusion Threshold in Neonates With Thrombocytopenia May Reduce Mortality
Researchers attempted to identify the appropriate platelet count transfusion threshold in preterm infants with severe thrombocytopenia.
Researchers Review Coagulation Risk Factors in Neonates and Children
The interactions between von Willebrand factors and its cleaving protease ADAMTS-13 recently emerged as risk factors for pediatric thromboembolism.
Statin Therapy May Reduce Thrombin Generation Potential in Patients With Thromboembolism
Statins may provide a therapeutic alternative to anticoagulant prophylaxis for venous thromboembolism.
Caplacizumab Cuts Time to Platelet Count Normalization in aTTP Patients
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
Upper Extremity Deep Vein Thrombosis May Be Linked to Post-Thrombotic Syndrome
Researchers conducted a systematic literature review to characterize the complications experienced by patients with upper extremity deep vein thrombosis.
Updated Clinical Practice Guidelines for Venous Thromboembolism: Pregnant and Pediatric Patients
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Updated Clinical Practice Guidelines for Venous Thromboembolism: Treatment Strategies
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Updated Clinical Practice Guidelines for Venous Thromboembolism: Diagnosis and Prophylaxis
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Eltrombopag May Improve Quality of Life for Patients With Immune Thrombocytopenia
Changes in health-related quality of life in patients with persistent/chronic immune thrombocytopenia were evaluated using 4 different tools.
High Risk of Thrombosis in Myeloproliferative Neoplasms, Underlying Cause Still Unclear
The prevalence of thrombotic events in patients with myeloproliferative neoplasms can be as high as 39% in some cases.
Controversy Continues Over Relationship Between VTE and Testosterone Therapy
Current clinical data are insufficient to confirm or deny the potential association between risk for VTE and testosterone therapy.
Anticoagulant Therapies in Patients With Iliofemoral Deep Vein Thrombosis
No differences were observed in patency rates or incidence of post-thrombotic syndrome in patients treated with rivaroxaban or a vitamin K antagonist.
Rivaroxaban May Decrease Risk of Major Bleeding in Patients With Venous Thromboembolism
Compared with warfarin, rivaroxaban was found to reduce the risk of overall, gastrointestinal, and intracranial bleeding.
Risk Factors Affecting Venous Thromboembolism in Older White and Black Women With Breast Cancer
Women with breast cancer were found to experience increased risk of developing VTE.
FDA to Review Doptelet for Treatment of Chronic Immune Thrombocytopenia
Doptelet is a thrombopoietin receptor agonist (TPO-RA) that was approved in May 2018 to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Management of Venous Thrombosis in Unusual Sites
The incidence, pathophysiology, provoking factors, and recommended treatments for several types of unusual thrombosis were summarized in a review article.
Want to read more?
Please login or register first to view this content.
Next post in Thrombotic Disorders
